secwatch / observer
8-K filed November 2, 2022, 7:59 PM ET ticker CVS CIK 0000064803
earnings confidence high sentiment positive materiality 0.75

CVS Q3 GAAP loss $(2.60) on opioid/LTC charges; adj. EPS $2.09 beat; raises full-year adj. guidance

CVS HEALTH Corp

2022-Q3 EPS reported $1.40 revenue$238,621,000,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVS HEALTH Corp reported three months ended September 30, 2022 results: revenue $81.2 billion, EPS $(2.60). Guidance raised.

Period
three months ended September 30, 2022
Revenue
$81.2 billion
EPS
$(2.60)
Guidance
raised
Result
reported results
Exact text from the filing
Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2022. THIRD QUARTER RESULTS KEY FINANCIAL DATA • Total revenues increased to $81.2 billion, up 10.0% compared to prior year • GAAP loss per share of $(2.60), inclusive of $5.2 billion pre-tax opioid litigation charges and a $2.5 billion pre-tax loss on assets held for
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVS HEALTH Corp reported 2022 (year-to-date) results: revenue $238.6 billion, EPS $1.40. Guidance raised.

Period
2022 (year-to-date)
Revenue
$238.6 billion
EPS
$1.40
Guidance
raised
Result
reported results
Exact text from the filing
Total revenues increased to $238.6 billion, up 10.7% compared to prior year
View on SEC.gov

Browse all earnings releases →

CVS HEALTH Corp filing history →

Source: SEC EDGAR
accession 0000064803-22-000037
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.